Cellectis (CLLS) Profit After Tax (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.50% |
| Dec 31, 2025 | 36.24% |
| Sep 30, 2025 | -73.89% |
| Jun 30, 2025 | -30.94% |
| Mar 31, 2025 | -406.11% |
| Dec 31, 2024 | 125.69% |
| Sep 30, 2024 | -17.47% |
| Jun 30, 2024 | -447.81% |
| Mar 31, 2024 | 111.24% |
| Dec 31, 2023 | -187.08% |
| Sep 30, 2023 | -5.05% |
| Jun 30, 2023 | 44.67% |
| Mar 31, 2023 | -5.30% |
| Dec 31, 2022 | 8.66% |
| Sep 30, 2022 | 38.52% |
| Jun 30, 2022 | -59.37% |
| Mar 31, 2022 | -13.64% |
| Dec 31, 2021 | 68.52% |
| Sep 30, 2021 | -72.25% |
| Jun 30, 2021 | -237.46% |
| Mar 31, 2021 | -132.84% |
| Dec 31, 2020 | 239.07% |
| Sep 30, 2020 | -174.95% |
| Jun 30, 2020 | -173.61% |
| Mar 31, 2020 | 140.34% |
| Dec 31, 2019 | -111.24% |
| Sep 30, 2019 | 46.82% |
| Jun 30, 2019 | -140.27% |
| Mar 31, 2019 | 41.50% |
| Dec 31, 2018 | -2.97% |
| Sep 30, 2018 | -159.94% |
| Jun 30, 2018 | 63.98% |
| Mar 31, 2018 | 5.86% |
| Dec 31, 2017 | 60.26% |
| Sep 30, 2017 | -172.68% |
| Jun 30, 2017 | -34.06% |
| Mar 31, 2017 | -46.97% |
| Dec 31, 2016 | 4.30% |
| Sep 30, 2016 | -98.89% |
| Jun 30, 2016 | 78.25% |
| Mar 31, 2016 | -459.73% |
| Dec 31, 2015 | 163.62% |
| Sep 30, 2015 | 42.04% |
| Jun 30, 2015 | -443.28% |
| Mar 31, 2015 | 28,447.89% |